Lupin launches Minocycline Hydrochloride extended release tablets in US

Written by Farhat Nasim Published On 2019-02-27T09:40:37+05:30 | Updated On 16 Aug 2021 4:30 PM IST

The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said.

Mumbai: Drug major, Lupin has recently launched Minocycline Hydrochloride extended-release tablets in the US market. Minocycline Hydrochloride is used to treat inflammatory lesions of acne. However, the tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said.

Also Read: Lupin gets USFDA nod to Methylprednisolone tablets to treat inflammation

As per IQVIA MAT December 2018 data, the product had annual sales of around $76.8 million in the US, Lupin said.

The product is a generic version of Medicis Pharmaceutical Corporation's Solodyn tablets in the same strength, it added.

The tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older, it added.

Lupin was founded in 1968 by Desh Bandhu Gupta, then an Associate Professor at BITS-Pilani, Rajasthan. Gupta died on 26 June 2017 and was replaced as chairman by his wife, Manju Deshbandhu Gupta.

The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Also Read: Relief to Lupin: High court removes ban its diabetes drug Gluconorm P 30

acne drugacne drug teenageracne tabletslatest acne drugLupinLupin drugsminocyclineminocycline hydrochlorideMinocycline Hydrochloride tabletspharmaPharmaceuticalsskin inflammationUSUSFDA

Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here